Myokardia Inc (MYOK) Given Average Recommendation of “Buy” by Brokerages
Shares of Myokardia Inc (NASDAQ:MYOK) have earned a consensus rating of “Buy” from the ten brokerages that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $55.67.
MYOK has been the subject of several research reports. Zacks Investment Research downgraded Myokardia from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. TheStreet downgraded Myokardia from a “c” rating to a “d+” rating in a research note on Friday, November 3rd. ValuEngine downgraded Myokardia from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. JPMorgan Chase & Co. initiated coverage on Myokardia in a research note on Tuesday, December 12th. They issued an “overweight” rating and a $54.00 target price for the company. Finally, BidaskClub upgraded Myokardia from a “sell” rating to a “hold” rating in a research note on Tuesday, December 12th.
In related news, CEO Anastasios Gianakakos sold 4,300 shares of the firm’s stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $40.23, for a total value of $172,989.00. Following the transaction, the chief executive officer now owns 513,417 shares of the company’s stock, valued at approximately $20,654,765.91. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Kevin P. Starr sold 816,326 shares of the firm’s stock in a transaction dated Wednesday, January 3rd. The shares were sold at an average price of $42.00, for a total transaction of $34,285,692.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 841,626 shares of company stock worth $35,396,501. 33.40% of the stock is owned by insiders.
Shares of Myokardia (MYOK) traded down $1.00 on Friday, hitting $53.05. The stock had a trading volume of 260,690 shares, compared to its average volume of 440,849. The firm has a market cap of $1,860.00 and a P/E ratio of -71.69. Myokardia has a 12 month low of $10.80 and a 12 month high of $55.40.
Myokardia (NASDAQ:MYOK) last issued its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.42) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.42). The company had revenue of $5.63 million during the quarter, compared to the consensus estimate of $6.10 million. Myokardia had a negative return on equity of 14.92% and a negative net margin of 53.49%. The firm’s revenue for the quarter was up 58.6% compared to the same quarter last year. During the same period last year, the business posted ($0.35) EPS. research analysts forecast that Myokardia will post -1.62 EPS for the current year.
MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.
Receive News & Ratings for Myokardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myokardia and related companies with MarketBeat.com's FREE daily email newsletter.